'Covid Vaccine Maker Novavax Sees A Pathway To Survival – But It Won't Be Easy' - CNBC
Portfolio Pulse from Benzinga Newsdesk
Novavax aims to survive by developing an updated Covid vaccine before the fall season and reducing costs. However, the company faces challenges such as competing with Pfizer and Moderna in the commercial vaccine market and a pending $700 million arbitration with Gavi.
June 14, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novavax's survival depends on its ability to develop an updated Covid vaccine and reduce costs, but it faces competition from Pfizer and Moderna, and a pending $700 million arbitration with Gavi.
Novavax's updated Covid vaccine and cost reduction efforts are crucial for its survival. However, competition from Pfizer and Moderna, as well as the pending arbitration with Gavi, create uncertainty for the company's future. This makes it difficult to predict a clear short-term price direction for NVAX.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100